New Review in Clinical and Experimental Medicine
Published:
We are pleased to announce that our latest paper Innovations in Biomarker Stratification for Precision Oncology has been published in Clinical and Experimental Medicine.
This review addresses a central challenge in modern cancer research: how to reliably translate continuous molecular biomarkers into clinically actionable insights. While survival analysis underpins much of precision oncology, commonly used approaches often rely on arbitrary thresholds - such as median splits - that can obscure biologically meaningful patterns and limit reproducibility across patient cohorts.
In our manuscript, we provide a comprehensive overview of current strategies for biomarker stratification, spanning conventional statistical methods, data-driven threshold selection, and emerging machine learning approaches. We critically evaluate how these methods handle key challenges including tumour heterogeneity, confounding, and overfitting, and assess their suitability for clinical translation.
A major focus of the paper is the need to move beyond simplistic dichotomisation towards more robust, multivariate frameworks that integrate molecular and clinical data. We highlight how such approaches can improve risk stratification, support more reliable biomarker validation, and ultimately enhance decision-making in oncology.
Importantly, the review emphasises that methodological innovation alone is not sufficient. Reproducibility, interpretability, and rigorous external validation must be central to biomarker development if precision oncology is to deliver meaningful clinical benefit.
This work reflects a core research theme of the group and contributes to ongoing efforts to develop scalable, reproducible analytical frameworks for translational cancer research and clinical oncology.
